HMG- CoA- reduktasehæmmere som i høj grad er afhængige af CYP3A4 metabolisme, såsom lovastatin og simvastatin, forventes at øge plasmakoncentrationen væsentligt, når disse stoffer indtages sammen med VIRACEPT.
HMG-CoA reductase inhibitors which are highly dependent on CYP3A4 metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when co-administered with VIRACEPT.